AesMed Korea

19/03/2026

SGF57 in 3 Parts: The Evidence Story Behind AGF39 (Clinical → Conference → Journal)

We’re excited to share a new 3-part series on the AesMed Official Blog featuring SGF57 - the original formula that helped shape AesMed’s evidence-first approach and the credibility story behind AGF39.

This series is written for both hair-loss–interested readers and medical professionals, translating clinical and academic evidence into clear, accessible insights without overclaiming.

📌 Series Theme: Evidence Continuity (Clinical → Conference → Journal)
Across three posts, we explore how SGF57 was studied, measured, and shared through scientific channels.

✅ What’s Inside the Series
Part 1. SGF57: The Original Blueprint Behind AGF39
• The origin story of SGF57 and why “growth factors + delivery” became essential

Part 2. The Clinical Study Behind the Original SGF57 Formula
• A plain-language walkthrough of a peer-reviewed pilot study in female pattern hair loss (FPHL)
• Study design, protocol, measured outcomes, and safety observations

Part 3. From Conference Posters to Credibility: How SGF57 Built Trust
• How academic posters (2013–2014) expanded clinical insight
• Protocol optimization highlights, including microneedle depth, and why journals matter

🔗 Read the full series on the AesMed Official Blog.
https://aesmed.blog/sgf57-the-original-blueprint-behind-agf39-series-part-1/

For clinics and professional partners who would like an evidence-focused briefing pack, please contact us through our official inquiry channel.

Discover SGF57, the original formula behind AGF39, and how “growth factors + microneedling delivery” evolved into clinical, conference, and peer-reviewed

10/03/2026

🔬 AGF39: Clinical Experience, Real-World Data, and Global Adoption

Korean Cytokines Mesotherapy for Hair Regrowth – Part 4
In the final part of our blog series on Korean Cytokines Mesotherapy for Hair Regrowth, we explore the clinical experience and global adoption of AGF39, AesMed’s proprietary cytokine-based solution for professional alopecia care.

AGF39 has been widely used in hair-loss treatment hospitals and specialized clinics across Korea, Japan, China, and other regions, accumulating extensive real-world clinical experience and high procedure volume.

Through its integration with
CytoMesopecia – Cytokines Mesotherapy for Alopecia,
AGF39 helps support follicular regeneration, maintain the anagen phase, and improve the scalp microenvironment for effective hair regrowth strategies.

🌏 With growing adoption in the global hair-loss treatment field, AGF39 continues to strengthen its credibility through clinical application, practitioner experience, and scientific understanding of cytokine signaling in hair biology.

📖 Read the full article on our official blog
🔗 https://aesmed.blog/agf39-clinical-experience-real-world-data-and-global-adoption-part-4/

AGF39: Clinical Experience, Real-World Data, and Global Adoption

04/03/2026

📢 Meet AesMed at KIMES 2026

AesMed is excited to announce our participation in KIMES 2026 – The 41st Korea International Medical & Hospital Equipment Show, one of Asia’s leading medical exhibitions.
At this exhibition, AesMed will introduce its latest innovations in hair-loss treatment and regenerative scalp care, including:

🔬 CytoMesopecia – Cytokines Mesotherapy for Alopecia
🧬 AGF39 cytokine-based clinical solution
🧴 Advance Follicle Shampoo for professional scalp care

We warmly invite healthcare professionals, industry partners, and global visitors to meet our team and explore new opportunities for collaboration.

📍 Booth No.: A816
📅 March 19 – 22, 2026
📍 COEX Convention & Exhibition Center, Seoul

Opening Hours
• Mar 19 – 21 : 10:00 AM – 6:00 PM
• Mar 22 : 10:00 AM – 5:00 PM

Learn more about the exhibition:
🔗 https://kimes.kr/eng/exhibitor/detail/2068692591_2026_kor

We look forward to welcoming you at AesMed Booth A816.

24/02/2026

CytoMesopecia: Turning Cytokine Science into a Reproducible Clinical Framework (Part 3)

In cytokines mesotherapy, one key challenge has become clear in real-world practice:
How do we translate cytokine science into a structured, consistent, and clinically meaningful protocol?

AesMed’s answer is CytoMesopecia – Cytokines Mesotherapy for Alopecia, a proprietary framework designed to move beyond ad-hoc sessions and support standardized, scalable, long-term care.

What CytoMesopecia focuses on
• Biological modulation (not overstimulation) : Supports balanced cytokine signaling for sustainable regrowth
• Targeted dermal delivery : Mesotherapy delivery to the scalp dermis for localized effectiveness
• Integration with clinical practice : Designed to complement pharmacotherapy, PRP, devices, and post-transplant care

Clinical application logic
• Scalp & follicular assessment
• Interval planning and consistent protocol use
• Monitoring + adjustment based on patient response
• Positioning cytokines mesotherapy as a platform therapy, not a one-time procedure

Up next (Part 4): AGF39
CytoMesopecia created the need for a cytokine solution aligned with balance, precision, and usability—leading to AGF39, AesMed’s proprietary cytokine solution.

👉 Read Part 3 here: https://aesmed.blog/cytomesopecia-cytokines-mesotherapy-for-alopecia/

Blog Series Part 3

11/02/2026

Why Korea Leads Cytokines Mesotherapy for Hair Regrowth

Korea has emerged as a global leader in cytokines-based mesotherapy for hair regrowth and the reason goes beyond innovation alone.

🔬 High Clinical Volume
Korean hair-loss specialty clinics perform a significant number of procedures annually, allowing continuous protocol refinement and real-world validation.

🧬 Integration of Regenerative Medicine
Advanced dermatology and regenerative science have enabled a deeper understanding of follicular signaling and microenvironment balance.

📊 Clinical Precision & Reproducibility
Rather than trend-driven adoption, cytokines mesotherapy in Korea has grown through structured clinical application and measurable consistency.

🌏 Regional & Global Influence
Clinical experience developed in Korea has expanded into Japan, China, and other regions - shaping modern regenerative trichology practices.

At AesMed, this accumulated expertise is structured into
CytoMesopecia – Cytokines Mesotherapy for Alopecia,
a science-based framework designed for professional hair-loss treatment.

📖 Learn more on our official blog
🔗 https://aesmed.blog/why-korea-leads-cytokines-mesotherapy-for-hair-regrowth/

Blog Series Part 2

09/02/2026

📢 Lunar New Year Holiday Notice | AesMed

Please be informed that AesMed’s offices in South Korea will be closed for the Lunar New Year holiday during the following period:

📅 February 14 – February 18, 2026

During this time, business operations including inquiries and order processing will be temporarily paused. Normal operations will resume on February 19, 2026.

For urgent matters, please contact us via email:
📧 overseas@aesmed.co.kr

We will respond as soon as possible after the holiday.

Thank you for your understanding and continued support.
AesMed wishes you a happy, healthy, and prosperous Lunar New Year 🧧✨

04/02/2026

📘 AesMed Launches a New Blog Series on Hair Regrowth Science

AesMed is pleased to announce the launch of our new official blog series,
“Korean Cytokines Mesotherapy for Hair Regrowth.”

This four-part series explores how cytokine science is shaping the future of professional alopecia care from biological fundamentals to real-world clinical practice.

🔬 What the series covers:
• The role of cytokines in hair follicle regeneration
• Why Korea leads in cytokines mesotherapy
• AesMed’s structured framework, CytoMesopecia – Cytokines Mesotherapy for Alopecia
• Clinical experience and global adoption of AGF39

Through this series, AesMed aims to share science-based insights and practical perspectives with hair-loss specialists, industry professionals, global partners, and informed readers worldwide.

📖 Read the series on our official blog:
🔗 https://aesmed.blog/

We look forward to growing together through knowledge, collaboration, and innovation.

29/01/2026

🔬 The Rise of Cytokines in Hair Regrowth From Biology to Clinical Practice

Hair loss treatment is evolving.
Today, the focus is shifting from symptom suppression to biologically driven regeneration and at the center of this change are cytokines.

Cytokines are key signaling molecules that regulate cellular communication, inflammation control, and tissue regeneration. In hair biology, they play a critical role in hair follicle cycling, microenvironment balance, and anagen phase maintenance.

💡 Why Cytokines Matter in Hair Regrowth
• Hair follicles are dynamic mini-organs governed by biological signals
• Imbalanced cytokine signaling can lead to follicle miniaturization and hair thinning
• Regenerative strategies aim to restore balance not overstimulate

This scientific understanding has led to the rise of Korean Cytokines Mesotherapy, a professional approach that delivers cytokines directly to the scalp dermis to support follicular regeneration.

At AesMed, this philosophy is embodied in CytoMesopecia – Cytokines Mesotherapy for Alopecia, a framework designed to translate cytokine science into real-world clinical practice.

This post marks Part 1 of our blog series exploring how cytokine science is reshaping modern hair regrowth care.

📖 Read more on the AesMed official blog
🔗 https://aesmed.blog/the-rise-of-cytokines-in-hair-regrowth-from-biology-to-clinical-practice-part-1/

Blog Series Part 1

18/01/2026

🔬 AesMed at FUE ASIA SAARC Regional Workshop 2026 🌏

At the FUE ASIA SAARC Regional Workshop 2026, AesMed introduced its advanced treatment framework,
CytoMesopecia – Cytokines Mesotherapy for Alopecia, to the global hair-loss medical community.

At the core of CytoMesopecia is AGF39, AesMed’s proprietary cytokine-based solution.
AGF39 has been actively used in leading hair-loss treatment hospitals and clinics across Korea, Japan, China, and other Asian markets, accumulating one of the largest numbers of clinical procedures among cytokine mesotherapy solutions.

📊 Why AGF39 Matters
• Supported by extensive real-world clinical experience
• Designed for professional mesotherapy delivery to the scalp dermis
• Aims to optimize the follicular microenvironment and support anagen phase maintenance
• Easily integrated into daily clinical workflows and combination treatment protocols

At the conference, many medical professionals showed strong interest in AGF39’s clinical credibility, high procedure volume, and its role in advancing regenerative, biologically driven alopecia care beyond conventional approaches.

Through continued global engagement and collaboration, AesMed remains committed to supporting medical professionals with science-based solutions that reflect real clinical needs.

🔗 Learn more about AesMed: www.aesmed.co.kr

13/01/2026

✨ Welcome to 2026 with AesMed ✨

AesMed has proudly begun 2026 with new energy, new challenges, and a strong commitment to growth.

This year, we look forward to growing together with our valued industry partners, global buyers, medical professionals, and patient communities - advancing science, strengthening collaboration, and creating meaningful progress in hair-loss care.

Thank you for your trust and partnership.

Let’s make 2026 a year of shared growth and positive change - together. 🌱

31/12/2025

✨ AesMed at KALDAT 2025 Fall Scientific Meeting ✨
AesMed was pleased to participate as an exhibitor at KALDAT 2025 – the 51st Fall Scientific Meeting of the Korean Academy of Laser, Dermatology and Trichology, held in Seoul this December.

At the conference, AesMed introduced CytoMesopecia – Cytokines Mesotherapy for Alopecia, our advanced cytokine-based treatment concept designed to support hair follicle regeneration through biologically driven mesotherapy.

🔬 What is CytoMesopecia?
CytoMesopecia integrates cytokine science with targeted dermal delivery, focusing on:
• Optimization of the follicular microenvironment
• Regulation of hair growth cycle signaling
• Support for anagen phase maintenance
• A regenerative approach beyond conventional drug-centered therapies

Our booth welcomed many dermatologists and hair-loss specialists who showed strong interest in next-generation, science-based alopecia treatment strategies.

Through continued participation in academic conferences like KALDAT, AesMed remains committed to advancing evidence-based, biologically rational solutions and strengthening collaboration with the medical hair-loss community.

Thank you to all the professionals who visited and shared valuable insights with us.
We look forward to continuing the conversation and shaping the future of alopecia care together.

🔗 Learn more about AesMed: www.aesmed.co.kr

22/12/2025

🎄 Season’s Greetings from AesMed 🎉
As 2025 comes to a close, AesMed sends warm Christmas wishes and Happy New Year greetings for 2026 to our valued partner hospitals, industry professionals, and patients around the world.

Thank you for walking this journey with us - advancing science, strengthening collaboration, and supporting people affected by hair loss.

In 2026, AesMed looks forward to deepening global partnerships and continuing innovation through CytoMesopecia – Cytokines Mesotherapy for Alopecia, delivering hope, confidence, and science-driven solutions worldwide.

✨ Merry Christmas 2025
✨ Happy New Year 2026

With gratitude,
AesMed

🌐 www.aesmed.co.kr